| Biomarker ID | 1570 |
| PMID | 31060542 |
| Year | 2019 |
| Biomarker | BUB1B+CDC45+CDK1+CENPI+CLSPN+ERCC6L+EXO1+NCAPG+NUSAP1+RAD51+RRM2 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: MSKCC: [Univariate: 4.10 (95% CI: 2.08-8.1); Multivariate: 2.27 (95% CI: 1.05-4.91); Final Model: 2.35 (95% CI: 1.14-4.87)];CAM: [Univariate: 4.76 (95% CI: 1.8-12.59); Multivaraite: 4.28 (95% CI: 1.53-11.99); Final Model: 3.53 (95% CI: 1.31-9.51)];STO: [Univariate: 3.00 (95% CI: 1.65-5.44); Multivariate: 2.69 (95% CI: 1.46-6.11); Final Model: 2.89 (95% CI: 1.56-5.36)];TCGA: [Univariate: 2.94 (95% CI: 1.94-4.46); Multivariate: 1.96 (95% CI: 1.26-3.05); Final Model: 1.96 (95% CI: 1.26-3.05)] |
| Effect on Pathways | Pathways include (CDK1): Signal transduction, Immune system, Signaling by GPCR, Interleukin-2 signaling pathway, Disease;Pathways include (NCAPG): Aurora B signaling |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Four prostate cancer cohorts were used in this study to establish the prognostic value of the TMCC11 signature: MSKCC (GSE21032); Cambridge (GSE70768) and Stockholm (GSE70769), are microarray datasets, and the TCGA PRAD dataset |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Microarrays |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |